MCIM
AKRO

Meadow Creek Investment Management’s Akero Therapeutics AKRO Stock Holding History

Meadow Creek Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$14K Hold
616
– – ﹤0.01% 1339
2019
Q2 		$12K Buy
+616
New +$11.7K ﹤0.01% 1340

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Meadow Creek Investment Management's AKRO Position: Q3 2019 in Review

Meadow Creek Investment Management held its Akero Therapeutics (AKRO) position steady in Q3 2019 at 616 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1339.

Meadow Creek Investment Management first reported a position in AKRO in Q2 2019 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Meadow Creek Investment Management held 616 shares of Akero Therapeutics worth $14K as of Q3 2019.
  • Meadow Creek Investment Management left its Akero Therapeutics share count unchanged in Q3 2019.
  • Akero Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1339 holding.
  • Meadow Creek Investment Management first reported a position in Akero Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.